We have observed that Prostate-specific antigen (PSA) and prostate health index (PHI) have been utilized as biomarkers for prostate disease recognition. In this examination, we expected to assess the cost-adequacy of PHI for prostate malignancy location in Chinese men.We built up a Markov model for Chinese male patient matured 50–75 years of age. The PSA system was to offer TRUS-PB for all patients with raised PSA of 4–10 ng/mL. The PHI procedure was to offer PHI for patients with raised PSA of 4–10 ng/mL. TRUS-PB would just be offered for patients with PHI >35.0. Model information sources were removed from nearby information when accessible. The expense per quality-changed life years picked up for the two procedures were determined. The steady cost-viability proportions corresponding to the readiness to-pay (WTP) limit were thought about. Single direction affectability investigation and probabilistic affectability examination were performed. Cost-adequacy agreeableness bends were likewise built.
Reference link- https://www.nature.com/articles/s41391-020-0243-1
